Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Rachna T. Shroff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0066-2672; OpenAlex author ID A5012936802, A5159847353; NIH RePORTER profile ID 14398948. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
180
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 8 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers, 1 grant · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 36

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. First author DOI 10.1038/s41591-026-04327-4↗
  3. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  4. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  5. Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2025.05.22.655586↗
  6. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  7. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  8. The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? Last author DOI 10.1001/jamaoncol.2024.0870↗
  9. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  10. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  11. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  12. Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma. First author DOI 10.1016/j.hoc.2022.07.003↗
  13. Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. Co-author DOI 10.1186/s13148-022-01246-2↗
  14. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
  15. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  16. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  17. Pancreatic cancer. Last author DOI 10.1016/s0140-6736(20)30974-0↗
  18. Charging forward in locally advanced pancreatic cancer. First author DOI 10.1016/s2468-1253(19)30404-2↗
  19. What is the role of PARP inhibitors in pancreatic cancer? First author DOI 10.1080/14737140.2020.1816174↗
  20. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0224↗
  21. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Co-author DOI 10.21037/jgo.2019.10.05↗
  22. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  23. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  24. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  25. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  26. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… Co-author DOI 10.1186/s13045-018-0616-2↗
  27. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. Co-author DOI 10.1200/po.17.00316↗
  28. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗
  29. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Co-author DOI 10.1007/s00520-016-3553-z↗
  30. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  31. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  32. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  33. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2788-6↗
  34. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.04.031↗
  35. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Co-author DOI 10.1245/s10434-015-4854-z↗
  36. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Co-author DOI 10.1007/s13539-014-0145-y↗

Grants 1

  1. DNA methylation, Liquid Biopsy, and Pancreatic Cancer R21CA263132↗

Closest collaborators

The 25 strongest of 180 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gauri Rajani Varadhachary · 16 shared papers, 2014–2025 · strength 1.22
  2. Robert A. Wolff · 17 shared papers, 2014–2021 · strength 1.20
  3. Milind M. Javle · 16 shared papers, 2014–2021 · strength 1.14
  4. David R. Fogelman · 14 shared papers, 2014–2020 · strength 0.90
  5. Michael James Overman · 11 shared papers, 2014–2021 · strength 0.79
  6. Mark A. Nelson · 1 shared paper, 1 shared grant, 2022–2023 · strength 0.75
  7. Bernard W. Futscher · 1 shared paper, 1 shared grant, 2022–2023 · strength 0.75
  8. Shubham Pant · 5 shared papers, 2020–2025 · strength 0.63
  9. Jonathan D. Mizrahi · 5 shared papers, 2020–2021 · strength 0.61
  10. Anirban Maitra · 8 shared papers, 2016–2025 · strength 0.58
  11. Michael Jon Pishvaian · 3 shared papers, 2024–2025 · strength 0.56
  12. Matthew H. G. Katz · 9 shared papers, 2014–2019 · strength 0.47
  13. Jane Elizabeth Rogers · 4 shared papers, 2020–2021 · strength 0.44
  14. Rishi Surana · 3 shared papers, 2020–2024 · strength 0.44
  15. Jeffrey E. Lee · 8 shared papers, 2015–2019 · strength 0.43
  16. Eugene Jon Koay · 7 shared papers, 2016–2019 · strength 0.39
  17. Huamin Wang · 7 shared papers, 2015–2019 · strength 0.39
  18. Emil Lou · 2 shared papers, 2023–2025 · strength 0.37
  19. Harshabad Singh · 2 shared papers, 2024–2025 · strength 0.36
  20. Andrew J. Aguirre · 2 shared papers, 2024–2025 · strength 0.36
  21. Sanjay Goel · 2 shared papers, 2024–2025 · strength 0.36
  22. Priyadarshini Pathak · 1 shared paper, 2024 · strength 0.36
  23. Colin D. Weekes · 1 shared paper, 2024 · strength 0.36
  24. Jason B. Fleming · 7 shared papers, 2015–2019 · strength 0.35
  25. Jashodeep Datta · 2 shared papers, 2023–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.